AMAG Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (NASDAQ: AMAG) to Covis Group S.à r.l. (“Covis”). Under the terms of the deal, Covis will acquire AMAG for $13.75 per share in cash.

The AMAG merger investigation concerns whether the Board of AMAG has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.